BNR - CIK 0001792267
Burning Rock Biotech Ltd trades as BNR. In its fiscal 2025 annual report the company posted revenue of $77.16M, up 9.2% from the prior year and net income of -$7.92M. This page tracks Burning Rock Biotech Ltd through 166 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Burning Rock Biotech Ltd's revenue grew from $65.89M to $77.16M, a compound annual growth rate of 3.2%. Net profit margin expanded from -94.7% to -10.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| 20-F | - | 2026-04-28 |
| Insider trade | 4 | 2026-04-02 |
| New insider ownership | 3 | 2026-03-18 |
| New insider ownership | 3 | 2026-03-17 |
| New insider ownership | 3 | 2026-03-17 |
| New insider ownership | 3 | 2026-03-17 |
The largest companies sharing Burning Rock Biotech Ltd's SEC industry classification (services-medical laboratories).
Burning Rock Biotech Ltd reported revenue of $77.16M for fiscal year 2025, an increase of 9.2% year over year.
In its latest fiscal year Burning Rock Biotech Ltd reported a net loss of $7.92M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.